Lysergic acid dipropylamide

LSDP
Clinical data
Other namesLysergic acid dipropylamide; LSDP; LSDPr; LADP; N,N-Dipropyllysergamide; DPL
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
Identifiers
  • (6aR,9R)-7-methyl-N,N-dipropyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC22H29N3O
Molar mass351.494 g·mol−1
3D model (JSmol)
  • CCCN(CCC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C22H29N3O/c1-4-9-25(10-5-2)22(26)16-11-18-17-7-6-8-19-21(17)15(13-23-19)12-20(18)24(3)14-16/h6-8,11,13,16,20,23H,4-5,9-10,12,14H2,1-3H3/t16-,20-/m1/s1
  • Key:QKKQYCDPPPJVQI-OXQOHEQNSA-N

Lysergic acid dipropylamide (LSDP), also known as N,N-dipropyllysergamide (DPL), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the amide group has two propyl substitutions instead of two ethyl substituents.

The drug has about 10% or less of the potency of LSD as a psychedelic and its dose is greater than 1 mg orally. It has been reported however that, in contrast to LSD, LSDP produces LSD-like autonomic effects at much lower doses (<1 mg) than those at which its psychedelic effects occur. The drug was initially thought to be non-hallucinogenic after only being tested at sub-milligram doses.

LSDP was first described in the literature by Albert Hofmann and colleagues by 1955. Unlike various other LSD analogues, it was never given a specific code name (as in e.g. "LSD-25"). Its psychedelic effects were also reported by Hofmann.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.